original ) (raw )Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
Kim Papp
Journal of the European Academy of Dermatology and Venereology, 2020
View PDFchevron_right
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data
Huifeng Yun
Drug Safety, 2020
View PDFchevron_right
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Oliver Fitzgerald
Rheumatology and therapy, 2020
View PDFchevron_right
Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
Ana-maria Orbai
BMC Rheumatology
View PDFchevron_right
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Valderilio F Azevedo
The New England journal of medicine, 2017
View PDFchevron_right
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Valderilio F Azevedo
Rheumatology and Therapy, 2021
View PDFchevron_right
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
Ari Polachek
RMD Open
View PDFchevron_right
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
Shrikant Wagh
Arthritis & Rheumatology, 2019
View PDFchevron_right
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
Oliver Fitzgerald
Arthritis Research & Therapy, 2021
View PDFchevron_right
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
Joel Kremer
2019
View PDFchevron_right
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
Irmgadt Sariego
Lancet (London, England), 2017
View PDFchevron_right
Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
vibeke strand
Arthritis care & research, 2015
View PDFchevron_right
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
J. Gomez-Reino
Current Therapeutic Research, 2020
View PDFchevron_right
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study
Cristiano Moura
Arthritis research & therapy, 2018
View PDFchevron_right
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
Fowzia Ibrahim
Rheumatology (Oxford, England), 2012
View PDFchevron_right
Tofacitinib for the treatment of moderate-to-severe psoriasis
Maria Sole Chimenti
Expert Review of Clinical Immunology, 2015
View PDFchevron_right
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
Peter Taylor
RMD Open
View PDFchevron_right
Tofacitinib with Methotrexate in Third-Line Treatment of Patients with Active Rheumatoid Arthritis: Patient-Reported Outcomes from a Phase 3 Trial
vibeke strand
View PDFchevron_right
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Joel Kremer
International Journal of Rheumatic Diseases, 2016
View PDFchevron_right
Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
Joseph Cappelleri
RMD Open, 2021
View PDFchevron_right
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Joel Kremer
New England Journal of Medicine, 2012
View PDFchevron_right
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
vibeke strand
RMD open, 2016
View PDFchevron_right
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Joseph Cappelleri
RMD Open, 2019
View PDFchevron_right
Tofacitinib in patients with moderate to severe chronic plaque psoriasis: 2-year efficacy and safety in an open-label long-term extension study
Tsen-fang Tsai
Journal of the American Academy of Dermatology, 2016
View PDFchevron_right
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Jamie Geier
Annals of the rheumatic diseases, 2017
View PDFchevron_right
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Alan Worsley , Ying He
BMC Musculoskeletal Disorders, 2013
View PDFchevron_right
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
Mark Genovese
Annals of Internal Medicine, 2013
View PDFchevron_right
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study
Mauro Keiserman
Arthritis & Rheumatology
View PDFchevron_right
European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib
Maria Kózka
Therapeutics and Clinical Risk Management, 2017
View PDFchevron_right
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
vibeke strand
Rheumatology and therapy, 2018
View PDFchevron_right
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial
Kim Papp
The Journal of dermatology, 2017
View PDFchevron_right
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
Jonathan French
Arthritis & Rheumatism, 2012
View PDFchevron_right